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Abstract: We aimed in this case series to show Ga-68 DOTATATE uptake in relation with disease activity in sarcoidosis 
cases. 8 patients with previous diagnosis of sarcoidosis were included to the study. Ga-68 DOTATATE PET/CT was 
performed to evaluate of disease activity. Disease activity was described clinically by chest disease specialist by 
evaluation of lung function tests, serum ACE measurements and thorax CT. Correlation between Ga-68 DOTATATE 
uptake and disease activity was analyzed. Ga-68 DOTATATE PET/CT as a combination of SSR scintigraphy and 
anatomical imaging might be beneficial in the evaluation of active sarcoidosis. 
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INTRODUCTION 
Sarcoidosis is a chronic inflammatory disease with 
unknown origin. Description of disease activity could be 
beneficial to decide the need of treatment in some 
patients [1]. Ga-67 scintigraphy has been performed to 
evaluate disease activity and it is reported a good 
correlation exists between Ga-67 accumulation and 
active disease. Especially intense Ga-67 uptake in hilar 
and paratracheal lymph nodes is very specific for 
sarcoidosis [2]. Also somatostatin receptor scintigraphy 
has revealed superior than Ga-67 scintigraphy 
especially in the evaluation of extrapulmonary 
involvement [3].  
Ga-68 is generator produced radionuclide that 
decays by positron emission (42%) and electron 
capture (%41) into Zn-68 and has 68 minutes physical 
half-life. Several synthetic somatostatin analogues 
including DOTATATE have been labeled by Ga-68. 
Somatostatin receptor(SSR)s are expressed surface of 
the inflammatory cells as well as well differentiated 
neuroendocrine tumors. There were 5 different 
subtypes of SSRs. Ga-68 DOTATATE has high affinity 
to SSR subtype 2 and 5. As a positron emission 
tomography (PET) agent Ga-68 labeled somatostatin 
analogues have superior spatial resolution and higher 
sensitivity than single photon emission tomography 
(SPECT) agents. In the literature SSR expression of 
sarcoidosis has been showed by SPECT imaging. 
However as far as we know, role of positron emission 
tomography by Ga-68 labeled SSR scintigraphy has 
not been reported. 
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We aimed in this case series to show Ga-68 
DOTATATE uptake in relation with disease activity in 
sarcoidosis cases. 
MATERIAL AND METHOD 
8 patients with previous diagnosis of sarcoidosis 
were included to the study. A Ga-68 DOTATATE 
PET/CT was performed to evaluate of disease activity. 
Ga-68 was eluted from 740 MBq Ge-68/Ga-68 
generator system (Scintomics GmbH, Fürstenfeld- 
bruck, Germany). PET/CT images were acquired with 
Discovery ST PET/CT scanner (General Electric, 
Milwaukee, Wisconsin, USA). Synthesis of Ga-68 
DOTATATE was performed by automated synthesis 
unit (Scintomics GmbH, Fürstenfeldbruck, Germany). 
>95% purity was checked before administration to 
patient. Images were obtained approximately 1 hour 
after an intravenous injection of approximately 100 
MBq of Ga-68 DOTATATE. Whole body PET/CT 
imaging was performed while patients were in supine 
position from the vertex to the mid thighs. CT image 
was obtained from the integrated PET/CT scanner with 
the use of a standardized protocol involving 140 kV, 70 
mA, a tube rotation time of 0.5 s per rotation, a pitch of 
6 and a section thickness of 5 mm. immediately after 
the CT part, PET images were acquired for 5 minutes 
per bed position. PET images were reconstructed using 
non-contrast CT data for attenuation correction. 
PET/CT images were evaluated by visually for regions 
of pathologically increased tracer uptake that could not 
be accepted as normal physiologic activity. 
Disease activity was described clinically by chest 
disease specialist by evaluation of lung function tests, 
serum Angiotensin Converting Enzyme (ACE) 
measurements and thorax CT. Correlation between 
Ga-68 DOTATATE uptake and disease activity was 
analyzed. 
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RESULTS 
8 patients (mean age: 48±13.2, min-max: 27-60, 6F; 
2M) with previous diagnosis of sarcoidosis were 
included to the study. Mean serum ACE level of 
patients was calculated as 24.2±15.6 (min-max: 2-54). 
While thorax CT was totally normal in 3 patients, 
mediastinal-hilar lymph nodes were detected in the rest 
of them.  
In 3 out of 8 patients who had chronic inactive 
disease, Ga-68 DOTATATE PET/CT was normal. In 
the remaining 5 patients with active disease, different 
degree pathological Ga-68 DOTATATE accumulation 
was seen in the mediastinal lymph nodes (Figure 1a, 
1b, 2, 3). Additionally, in one patient Ga-68 
DOTATATE accumulation was detected in the parotid 
glands, in one patient in jugular, iliac and inguinal 
lymph nodes and in one patient both lungs which were 
accepted disease involvement. 
DISCUSSION 
Usage of somatostatin receptor scintigraphy in 
benign diseases has been described previously [4]. In 
chronic inflammatory diseases such as sarcoidosis, 
expression of somatostatin receptors has been known. 
Presence of somatostatin receptor subtype 2 was 
demonstrated on epithelioid cells and giant cells. The 
role of somatostatin receptor scintigraphy by In-111 
Octreotide and Tc-99m HYNIC-TOC in sarcoidosis has 
been showed in several studies [5, 6].  
Kwekkeboom et al have reported that lymph node 
involvement of 34 out of 46 patients have detected by 
SSR scintigraphy, whereas detection rate was 29 out of 
46 patients by CT and radiography. They have also 
reported a high accuracy rate in the detection of active 
parenchymal lung disease although it is lower in the 
detection of skin and liver involvements [7]. Lebtahi et 
al. have been compared Ga-67 and SRS scintigrapies. 
They reported that SRS scintigraphy has higher 
accuracy in the detection of both affected patients and 
affected sites [3]. Piotrowski et al. have compared the 
relation between clinical/laboratory markers and SSR 
scintigraphy in sarcoidosis. They claimed that 
discrepancies between scintigraphy and markers might 
be related with low resolution and specificity of 
scintigraphy [8].  
It is known that Ga-68 DOTATATE PET/CT has 
higher sensitivity than In-111 or Tc-99 m labeled 
somatostatin SPECT because of higher spatial 
resolution of PET. For this reason Ga-68 DOTATATE 
PET/CT might be more accurate than SSR SPECT. 
Because of lower specificity of SSR expression, Ga-68 
DOTATATE PET/CT can be performed in just 
previously histopathologically diagnosed patients. 
Additionally, it might have a role in the detection of 
extrathoracic involvement. Additionally, procedure of 
Ga-68 DOTATATE PET/CT is easier than Ga-67 
scintigraphy because there is not need of special 
preparation of patient and all procedure could be 
completed within 2 hours period. Another advantage of 
Ga-68 DOTATATE PET/CT is lower effective whole 
body radiation dose than Ga-67 citrate [7, 8]. For this 
reasons, Ga-68 DOTATATE PET/CT could be an 
alternative for evaluation of disease activation of 
sarcoidosis patients. 
We did not compare Ga-68 DOTATATE 
accumulation with serum markers because it would not 
be meaningful in limited number of patients. In this 
stage, we would like to share our initial results by 
reporting our case series. As a result of this limited 
number of patients, in addition to clinical examination 
and other laboratory parameters, Ga-68 DOTATATE 
PET/CT as a combination of SSR scintigraphy and 
anatomical imaging might be beneficial in the 
evaluation of active sarcoidosis. 
CASE 1 
26 years old, female patient underwent Ga-68 
DOTATATE PET/CT for evaluation of activation of 
sarcoidosis. 15 days before she has been diagnosed 
as sarcoidosis by mediastinal lymph node biopsy after 
presentation with weakness and weight loss. In 
Contrast Enhanced Thorax CT, multiple enlarged 
mediastinal lymph nodes were detected. Serum ACE 
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level was measured as 15U/L. Intense Ga-68 
DOTATATE accumulation was seen in mediastinal, 
bilateral hilar and bronchopulmonary lymph nodes in 
transaxial fused images of thorax (Figure 1a) and 
maximum intensity projection (MIP) images of whole 
body (Figure 1b). 
 
(1b) 
CASE 2 
54 years old female patient who has been followed 
up for sarcoidosis for several years. She underwent 
Ga-68 DOTATATE PET/CT following Ga-67 planar 
imaging for evaluation of disease activity because 
withdrawal of steroid treatment was planned. Intense 
Ga-68 uptake was seen in paratracheal, prevascular 
and subcarinal lymph nodes in transaxial fused images 
of thorax (Figure 2). Steroid treatment was continued in 
that patient.  
 
   (2) 
CASE 3 
53 years old, female patient, she underwent Ga-68 
DOTATATE PET/CT for initial evaluation of disease 
activity. Serum ACE level was measured as 13U/L and 
thorax CT revealed mediastinal and bilateral hilar 
lymph nodes. In axial fused images of thorax (Figure 3) 
Ga-68 DOTATATE accumulation was seen in 
mediastinal, bilateral hilar lymph nodes and bilateral 
lung parenchyma.  
 
   (3) 
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